Search Tag: aspirin

2022 22 Mar

Thrombotic events are common in patients hospitalised with COVID-19. Platelet activation has been implicated in the COVID-19 inflammatory response. However, the efficacy of antiplatelet therapy in critically ill patients with COVID-19 is still uncertain.  The Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia...Read more

2021 14 Dec

The use of aspirin has been proposed as a treatment for COVID-19 because of its anti-thrombotic properties. Thrombosis is a key feature of COVID-19, with 5-30% of hospitalised patients having a major venous thromboembolic event and up to 3% having an arterial thromboembolic event.   The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial is...Read more

2016 17 May

Results of a trial of helmet-based ventilation have shown that using a transparent air-tight helmet instead of a facemask helped critically ill patients breathe better and reduced their need for mechanical ventilation. In the trial, patients who were treated with helmet ventilation spent less time in the intensive care unit and lower mortality. The...Read more

2014 17 Nov

According to a new study, neither aspirin nor clonidine reduce the risk of acute kidney injury when used in patients undergoing non-cardiac surgery. The study has been published in JAMA and will be presented at the American Society of Nephrology’s Annual Kidney Week meeting.   Approximately 10 percent of the 200 million adults undergoing major...Read more